Neoadjuvant chemotherapy in locally advanced colon cancer.<b>A phase II trial</b>

Jakobsen, Anders; Andersen, Fahimeh; Fischer, Anders; Jensen, Lars Henrik; Jørgensen, Jens Christian Riis; Larsen, Olav; Lindebjerg, Jan; Pløen, John; Rafaelsen, Søren Rafael; Vilandt, Jesper

doi:10.3109/0284186x.2015.1037007

Cited by 92 publications

(97 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This translational study refers to a previous phase II trial of neoadjuvant chemotherapy in patients with locally advanced colon cancer [12]. The present study population represents 65 of the 71 patients who completed neoadjuvant chemotherapy followed by operation between August 2010 and September 2013.…”

Section: Study Populationmentioning

confidence: 99%

“…All patients were !18 years, of performance status (PS) 2 and had a T 3 tumor with extramural tumor invasion (ETI) > 5 mm or a T 4 tumor based on CT scans. Selection criteria and follow-up have previously been specified [12]. Patients were followed according to the protocol for up to three years post-operatively.…”

Section: Study Populationmentioning

confidence: 99%

“…pathological complete response with no residual tumor, to 5, referring to no response. All patients were followed as previously specified [12]. …”

Section: Treatmentmentioning

confidence: 99%

“…The initial phase II experience indicates that a substantial proportion of these patients may convert to a low risk status at the time of operation, eliminating the need for adjuvant chemotherapy [12]. Whether TSR after exposure to neoadjuvant chemotherapy still holds prognostic value after the operation has never been investigated before.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Tumor–stroma ratio predicts recurrence in patients with colon cancer treated with neoadjuvant chemotherapy

et al. 2017

Self Cite

View full text Add to dashboard Cite

Material and methods: This study included 65 patients with colon cancer treated with neoadjuvant chemotherapy in a phase II trial. All patients were planned for three cycles of capecitabine and oxaliplatin before surgery. Hematoxylin and eosin stained tissue sections from surgically resected primary tumors were sampled and analyzed by conventional microscopy. Patients were divided into stromahigh (>50%, i.e. TSR low) and stroma-low ( 50%, i.e. TSR high) for the comparison with clinical data. Results: A low TSR was found in 47% of the surgically resected primary tumors and correlated to a significantly higher T-and N-category compared, to tumors with a high TSR (p < .01). A low TSR was also significantly associated with disease recurrence (p ¼ .008), translating into significant differences in disease free survival (DFS) and overall survival, p < .002. The 5-year DFS rate for patients with a low TSR was 55%, compared to 94% in the group of patients with a high TSR. Conclusions: TSR assessed in the surgically resected primary tumor from patients with locally advanced colon cancer treated with neoadjuvant chemotherapy provides prognostic value and may serve as a relevant parameter in selecting patients for post-operative treatment.

show abstract

Section: Study Populationmentioning

confidence: 99%

Section: Study Populationmentioning

confidence: 99%

“…pathological complete response with no residual tumor, to 5, referring to no response. All patients were followed as previously specified [12]. …”

Section: Treatmentmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Tumor–stroma ratio predicts recurrence in patients with colon cancer treated with neoadjuvant chemotherapy

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…Two phase II trials, one randomized and both including colon cancer patients with T3 tumours with extramural tumour invasion more than 5 mm or with pT4 tumours, showed encouraging pathological responses in FOLFOX/ XELOX-treated patients with or without panitumumab [54,55]. Those responding well to neo-adjuvant treatment also seemed to have a better DFS than did those requiring also postoperative chemotherapy.…”

Section: Neo-adjuvant Rather Than Adjuvant Chemotherapymentioning

confidence: 99%